Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 49 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Christodoulou, Christos [Clear All Filters]
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative..
Oncotarget. 11(1), 1-14.
(2020). Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?.
Cancer Immunol Immunother.
(2020). The Role of CXCL13 and CXCL9 in Early Breast Cancer..
Clin Breast Cancer. 20(1), e36-e53.
(2020). Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer..
Anticancer Res. 39(4), 2129-2138.
(2019). Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab..
ESMO Open. 4(2), e000441.
(2019). Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer..
Cancer Genomics Proteomics. 16(3), 195-206.
(2019). Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab..
Transl Oncol. 12(5), 739-748.
(2019). Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer..
ESMO Open. 4(2), e000474.
(2019). Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome..
Clin Breast Cancer. 19(2), 113-125.e4.
(2019). Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab..
Cancer Genomics Proteomics. 15(6), 461-471.
(2018). Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study..
PLoS One. 13(12), e0207707.
(2018). Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer..
Oncotarget. 9(86), 35623-35638.
(2018). Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group..
J Transl Med. 15(1), 30.
(2017). Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients..
World J Urol. 35(3), 411-419.
(2017). The fate of BRCA1-related germline mutations in triple-negative breast tumors..
Am J Cancer Res. 7(1), 98-114.
(2017). Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer..
Anticancer Res. 37(5), 2323-2334.
(2017). Protein expression patterns of cell cycle regulators in operable breast cancer..
PLoS One. 12(8), e0180489.
(2017). Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO..
Ann Gastroenterol. 29(1), 18-23.
(2016). Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO)..
Ann Gastroenterol. 29(4), 390-416.
(2016). Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO..
Ann Gastroenterol. 29(1), 3-17.
(2016). Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO)..
Ann Gastroenterol. 29(2), 103-26.
(2016). Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study..
PLoS One. 11(10), e0164013.
(2016). Disease evolution and heterogeneity in bilateral breast cancer..
Am J Cancer Res. 6(11), 2611-2630.
(2016). Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes..
Breast Cancer Res Treat. 158(2), 307-21.
(2016).
(2016).